BlueRun Ventures | BlueRun Ventures Continues to Double Down, Zhitai Bio Closes Nearly RMB 200 Million Series B+ Round
Focused on developing recombinant protein therapeutics using an *E. coli*-based technology platform.
Focused on developing recombinant protein therapeutics using an *E. coli*-based technology platform.
Last week, ChinaVenture released its "2022–2023 Investor Rankings," marking the 17th consecutive year the independent third-party organization has published its China Venture Capital and Private Equity rankings — the "ChinaVenture List." The rankings draw on CVSource data and evaluate investors across four metrics: investments, exits, portfolio projects under management, and industry influence, measured over the period from July 1, 2020, to October 31, 2023. Through
Counselor Vitality
Focused on the mass production progress of separators and electrode products.
**Last week we launched recruitment for the Global Young PhD Fellow (GYPF), seeking outstanding technical founders at home and abroad.** **Global Young PhD Fellow is a joint initiative by Linear Capital and Linear Capital portfolio companies, dedicated to supporting young people — whether aspiring to build tech startups, currently in the early stages of entrepreneurship, or hoping to understand how China's best tech companies grow.**
Before taking responsibility for a new world, GPs must first answer to their LPs.
To prescribe the right medicine, you first need to understand the pathology.
The OpenAI Palace Drama: A Complete Account
You never know what tomorrow will bring.
Nothing is more dangerous for an operator than the delusion that "I'm already doing great."